Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTUS: anifrolumab in Chinese patients with active moderate-to-severe systemic lupus erythematosus
CTR20262997Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Aug 2026; status: active.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20262997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262997.